Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Volume 17 - Issue 8 - August, 2005

Prospective Native Coronary Artery Stenosis Treated with Sirolimus-Eluting Stent (ONASSIS) Registry — Acute Results and Mid-Term
08/01/2008
Vassilis Voudris, MD, Elias Alexopoulos, MD, Panagiotis Karyofillis, MD, John Malakos, MD, Athanasios Manginas, MD, Constantinos Spargias, MD, Gregory Pavlides, MD, Sotirios Patsilinakos, MD, Alexandros Anyfantakis, MD, Dennis V. Cokkinos, MD
Vassilis Voudris, MD, Elias Alexopoul...
Percutaneous coronary intervention is an established method of nonsurgical coronary revascularization, accounting for more than 1,500,000 annual procedures worldwide.1 Despite technical advancements in recent years, with coronary stenting...
Percutaneous coronary intervention is an established method of nonsurgical coronary revascularization, accounting for more than 1,500,000 annual procedures worldwide.1 Despite technical advancements in recent years, with coronary stenting...
Percutaneous coronary...
08/01/2008
Journal of Invasive Cardiology
Randomized, Controlled Study of Long-Acting Local Anesthetic (levobupivacaine) in Femoral Artery Sheath Management during and af
08/01/2008
Hannah M. Timlin, BSc, Sarah A. Carnaffin, RGN, Ian R. Starkey, MB, ChB, FRCP, David B. Northridge, MB, FRCP, Stephen J. Leslie, BSc, MB, ChB, MRCP, PhD
Hannah M. Timlin, BSc, Sarah A. Carn...
Percutaneous coronary intervention (PCI) is central to the management of patients with coronary artery disease. Vascular access is most commonly achieved via the femoral artery by inserting a vascular access sheath. To reduce the risk of...
Percutaneous coronary intervention (PCI) is central to the management of patients with coronary artery disease. Vascular access is most commonly achieved via the femoral artery by inserting a vascular access sheath. To reduce the risk of...
Percutaneous coronary...
08/01/2008
Journal of Invasive Cardiology
One-Year Clinical Outcome after Coronary Stenting of Very Small Vessels Using 2.25 mm Sirolimus- and Paclitaxel-Eluting Stents:
08/01/2008
Gastón A. Rodriguez-Granillo, MD, Marco Valgimigli, MD, Héctor M. Garcia-Garcia, MD, Andrew T.L. Ong, MD, Jiro Aoki, MD, Carlos A.G. van Mieghem, MD, Keiichi Tsuchida, MD, Georgios Sianos, MD, Eugene McFadden, MD, Willem J. van der Giessen, MD, Ron van Domburg, MD, Pim de Feyter, MD, Patrick W. Serruys, MD
Gastón A. Rodriguez-Granillo, MD, M...
Coronary stenting has significantly improved the angiographic and clinical outcomes in vessels with a reference diameter (RD) > 3 mm.1–5 However, several randomized trials have shown conflicting results when comparing coronary stenting...
Coronary stenting has significantly improved the angiographic and clinical outcomes in vessels with a reference diameter (RD) > 3 mm.1–5 However, several randomized trials have shown conflicting results when comparing coronary stenting...
Coronary stenting has...
08/01/2008
Journal of Invasive Cardiology
The Activated Clotting Time (ACT) Can Be Used to Monitor Enoxaparin and Dalteparin after Intravenous Administration
08/01/2008
Erdal Cavusoglu, MD*§, Manish Lakhani, MD*, Jonathan D. Marmur, MD*
Erdal Cavusoglu, MD*§, Manish Lakha...
A major advance in the use of heparin has been the development of low-molecular weight heparins (LMWH), which inhibit both the action (anti-IIa effect) and the generation (anti-Xa effect) of thrombin.1,2 Because of their ease of...
A major advance in the use of heparin has been the development of low-molecular weight heparins (LMWH), which inhibit both the action (anti-IIa effect) and the generation (anti-Xa effect) of thrombin.1,2 Because of their ease of...
A major advance in the use of...
08/01/2008
Journal of Invasive Cardiology
Impact of Glycemic Control on Occurrence of No-Reflow and 30-Day Outcomes in Diabetic Patients Undergoing Primary Angioplasty fo
08/01/2008
Chi Hang Lee, MBBS, Swee Guan Teo, MBBS, Eric Hong, MBBS, Hwee Bee Wong, MSc, Adrian Low, MBBS, Antono Sutandar, MD, Huay Cheem Tan, MBBS, Yean Teng Lim, MBBS
Chi Hang Lee, MBBS, Swee Guan Teo, M...
Primary percutaneous transluminal coronary angioplasty (PTCA) has been consistently demonstrated to be superior to thrombolytic therapy and is currently the recommended therapy for myocardial infarction (MI).1 However, no-reflow phenomenon...
Primary percutaneous transluminal coronary angioplasty (PTCA) has been consistently demonstrated to be superior to thrombolytic therapy and is currently the recommended therapy for myocardial infarction (MI).1 However, no-reflow phenomenon...
Primary percutaneous...
08/01/2008
Journal of Invasive Cardiology

Insights

Commentary
Pushing the Limits: Is there an Optimal Therapy for Very Small Vessels?
08/01/2008
Ariel Roguin, MD and Ehud Grenadier, MD
Ariel Roguin, MD and Ehud Grenadier, ...
Stent placement in coronary arteries larger than 3 mm in diameter has been proven to be superior to conventional balloon angioplasty (PTCA) in reducing the risk of restenosis and major adverse cardiac events (MACE). Subsequent improvements in...
Stent placement in coronary arteries larger than 3 mm in diameter has been proven to be superior to conventional balloon angioplasty (PTCA) in reducing the risk of restenosis and major adverse cardiac events (MACE). Subsequent improvements in...
Stent placement in coronary...
08/01/2008
Journal of Invasive Cardiology

Advertisement

Advertisement

Advertisement

News

A study led by researchers from Shinshu University propose a simplified risk-scoring model helps clinicians assess when patients with cardiogenic shock can be safely weaned off from MCS devices, such as VA-ECMO or IMPELLA, using easily measurable health indicators like blood pressure and heart function. Credit Sho Suzuki from Shinshu University
Mechanical Circulatory Support
A Simple Risk Score for Weaning Patients From Mechanical Circulatory Support
10/23/2024
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu...
10/23/2024
Cath Lab Digest
The initial cases with the Luna TMVR System were conducted in Paraguay and the Republic of Georgia and supported by leading US structural heart experts and the Tioga Cardiovascular team.
Mitral Valve intervention
Tioga Cardiovascular Announces First-In-Human Cases With Its Luna Transcatheter Mitral Valve Replacement (TMVR) System
10/23/2024
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a...
10/23/2024
Cath Lab Digest
CABG
Black Patients More Likely to Die After Coronary Bypass Surgery
10/22/2024
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients,...
10/22/2024
Cath Lab Digest
Medaxiom survey
Cardiology Compensation and Production Reflect Post-Pandemic Changes to Provider Market
10/21/2024
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH,...
10/21/2024
Cath Lab Digest
Cardiology Innovations
Philips Showcases Next Level Cardiology Innovations for Improved Patient Care at TCT 2024
10/21/2024
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of...
10/21/2024
Vascular Disease Management
Cardiovascular Risk After MI
Prolocor Announces Publication of Confirmatory Results From Multicenter 800 Patient Study in the Journal of the American College of Cardiology (JACC)
10/21/2024
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold...
10/21/2024
Vascular Disease Management
Pharmaceuticals
Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction
10/21/2024
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b,...
10/21/2024
Cath Lab Digest
PVD
Yale Study Finds Link Between Eczema and Peripheral Vascular Disease
10/21/2024
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred...
10/21/2024
Cath Lab Digest
plaque analysis
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease
10/18/2024
“We commend the AMA’s issuance of this upgraded Category I CPT billing code, which validates the technology’s clinical value in quantifying and characterizing plaque to help assess risk and personalize treatment for patients with coronary...
“We commend the AMA’s issuance of this upgraded Category I CPT billing code, which validates the technology’s clinical value in quantifying and characterizing plaque to help assess risk and personalize treatment for patients with coronary...
“We commend the AMA’s issuance...
10/18/2024
Cath Lab Digest
Hypertension
New Study Links Obesity to Elevated Hypertension Risk Among Young Middle Eastern Women
10/18/2024
“Young Middle Eastern women who are obese or overweight are facing a higher risk for the development of atherosclerotic cardiovascular disease and its associated risk factors like hypertension and Type Two diabetes,” said Mohammad Adnan Bani...
“Young Middle Eastern women who are obese or overweight are facing a higher risk for the development of atherosclerotic cardiovascular disease and its associated risk factors like hypertension and Type Two diabetes,” said Mohammad Adnan Bani...
“Young Middle Eastern women who...
10/18/2024
Cath Lab Digest

Advertisement

Advertisement

A study led by researchers from Shinshu University propose a simplified risk-scoring model helps clinicians assess when patients with cardiogenic shock can be safely weaned off from MCS devices, such as VA-ECMO or IMPELLA, using easily measurable health indicators like blood pressure and heart function. Credit Sho Suzuki from Shinshu University
Mechanical Circulatory Support
A Simple Risk Score for Weaning Patients From Mechanical Circulatory Support
10/23/2024
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu...
10/23/2024
Cath Lab Digest
Original Contribution
Intravascular Ultrasound in the Assessment of Coronary Artery Anomalies in Young Patients: A Tertiary Center Experience
10/23/2024
The authors describe a young population of patients with anomalous aortic origin of a coronary artery and myocardial bridge and review the safety of intravascular ultrasound in this population.
The authors describe a young population of patients with anomalous aortic origin of a coronary artery and myocardial bridge and review the safety of intravascular ultrasound in this population.
The authors describe a young...
10/23/2024
Journal of Invasive Cardiology
The initial cases with the Luna TMVR System were conducted in Paraguay and the Republic of Georgia and supported by leading US structural heart experts and the Tioga Cardiovascular team.
Mitral Valve intervention
Tioga Cardiovascular Announces First-In-Human Cases With Its Luna Transcatheter Mitral Valve Replacement (TMVR) System
10/23/2024
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a...
10/23/2024
Cath Lab Digest
Original Contribution
Comparison of Two Vascular Closure Device Strategies for Transfemoral Transcatheter Aortic Valve Replacement Using Suture-Based and Collagen-Plug-Based Techniques and Associated Vascular Complications
10/23/2024
The authors evaluated their experience with 2 distinct vascular closure device approaches using the Perclose ProGlide and the Angio-Seal, as well as the impact on vascular access site complications during transcatheter aortic valve...
The authors evaluated their experience with 2 distinct vascular closure device approaches using the Perclose ProGlide and the Angio-Seal, as well as the impact on vascular access site complications during transcatheter aortic valve...
The authors evaluated their...
10/23/2024
Journal of Invasive Cardiology
CABG
Black Patients More Likely to Die After Coronary Bypass Surgery
10/22/2024
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients,...
10/22/2024
Cath Lab Digest
Medaxiom survey
Cardiology Compensation and Production Reflect Post-Pandemic Changes to Provider Market
10/21/2024
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH,...
10/21/2024
Cath Lab Digest
Cardiology Innovations
Philips Showcases Next Level Cardiology Innovations for Improved Patient Care at TCT 2024
10/21/2024
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of...
10/21/2024
Vascular Disease Management
Cardiovascular Risk After MI
Prolocor Announces Publication of Confirmatory Results From Multicenter 800 Patient Study in the Journal of the American College of Cardiology (JACC)
10/21/2024
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold...
10/21/2024
Vascular Disease Management
Pharmaceuticals
Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction
10/21/2024
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b,...
10/21/2024
Cath Lab Digest
PVD
Yale Study Finds Link Between Eczema and Peripheral Vascular Disease
10/21/2024
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred...
10/21/2024
Cath Lab Digest

August 2005 Volume 17 Issue 8

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement